SCHEMBL6962847

SCHEMBL6962847

CC(C)c1ccccc1Sc1c(O)cc(-c2ccc(OCc3ccccc3)c(Cl)c2)oc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
PDK2 Q15119 1/20 0.38
MAOB P27338 3/20 0.38
CYP1A2 P05177 2/20 0.37
CYP1A1 P04798 1/20 0.37
MAOA P21397 1/20 0.36
PTPN1 P18031 1/20 0.36
GLRA1 P23415 1/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ABCB1 P08183 1/20 0.36
MAPT P10636 1/20 0.36
ACP1 P24666 1/20 0.35
PTPN12 Q05209 1/20 0.35
PTPN13 Q12923 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6965414 0.89 CYP1A1 (0.47) BCHEACHECYP1A2CYP1A1NPC1
SCHEMBL6965151 0.86 ABCB1 (0.45) ACHEMAOBCYP1A2CYP1A1MAOA
SCHEMBL8537357 0.84 ABCB1 (0.44) ACHEMAOBMAOANPC1RAB9A
SCHEMBL6965601 0.84 NPSR1 (0.42) CYP1A2NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL6954281 0.80 ALDH1A1 (0.42) MAOBCYP1A2CYP1A1NPC1RAB9A
SCHEMBL6963494 0.79 PTGES (0.43) BCHEACHEMAOBCYP1A2CYP1A1
SCHEMBL6966299 0.79 PPARD (0.41) CSNK2A2CSNK2BCSNK2A1
SCHEMBL6960106 0.79 CYP19A1 (0.39) ACHEMAOBMAOAPTPN1ABCB1
SCHEMBL6961039 0.79 SMN1; SMN2 (0.46) MAOBCYP1A2CYP1A1MAOASMN1; SMN2
SCHEMBL6954819 0.78 SYK (0.38) ACHEPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed